Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 80 full-time employees. The company went IPO on 2018-06-26. The firm is focused on developing and commercializing precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with rapamycin (mTOR) pathway driver alterations. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. The company has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.